Edwards Lifesciences Says PASCAL Tricuspid Repair System Meets Main Goal In Clasp II TR Study
Nov 2 (Reuters) - Edwards Lifesciences Corporation EW.N:
CLASP II TR TRIAL DEMONSTRATES SUPERIOR CLINICAL, QUALITY-OF-LIFE BENEFITS WITH EDWARDS PASCAL SYSTEM
EDWARDS LIFESCIENCES CORPORATION - PASCAL SYSTEM DEMONSTRATES SUPERIORITY IN CLASP II TR TRIAL AT SIX MONTHS
EDWARDS LIFESCIENCES CORPORATION - 80% OF PASCAL PATIENTS ACHIEVE ≤ MODERATE TR AT 1 YEAR VERSUS 30% CONTROL
Further company coverage: EW.N